N@N

Fresenius Medical Care Introduces 2008T Hemodialysis Delivery System at Renal Week 2010

^{Published on 2010-11-18 07:05:49 - Market Wire}
 

DENVER--([ BUSINESS WIRE ])--Fresenius Medical Care AG & Co. KGaA (FWB: FME) (NYSE: FMS), the worlda™s largest provider of dialysis products and services, today launched the 2008T, a smart dialysis platform featuring Fresenius Clinical Data Exchange (CDX), at the American Society of Nephrologya™s 43rd Annual Meeting and Scientific Exposition in Denver, CO. This is the first fully integrated therapy and management information system in the market and was developed to help physicians and clinic operators adjust to the new bundled payment environment due to take effect in January, 2011.

"This is a truly exciting development for those of us on the front lines of dialysis care"

The 2008T hemodialysis delivery system is designed to provide the world-class dialysis treatment the industry has come to expect from Fresenius Medical Care, the long-established market leader in hemodialysis equipment in North America. It combines the Companya™s most advanced hemodialysis delivery system with Fresenius Clinical Data Exchange (CDX) to provide caregivers, for the first time, chair side access to both dialysis treatment and medical information system data to facilitate real-time adjustments to therapy and care plans. This integrated approach streamlines workflow, maximizes data collection for comprehensive billing, and is designed to reduce risk associated with cross-contamination of dialysis and MIS equipment in the treatment facility. The 2008T was developed in close association with the Renal Research Institute, one of the preeminent research institutions in the United States focused on improving the clinical care and quality of life of patients with chronic kidney disease.

2008T key features include:

• CDX module electronically independent of dialysis function
• Enables MIS software from 3^rd party vendors as well as the Companya™s proprietary systems
• Full size QWERTY keyboard to simplify real-time chair side data entry
• Integrated IT terminal saves floor space and reduces risk of cross contamination and potential compliance violations
• Seamless tracking of billable items
• Automatic return from MIS to machine display in alarm conditions
• Designed to promote compliance with CMS Conditions for Coverage

aFresenius Medical Care has always led the nephrology industry in driving technological innovation to the market and continuously evaluating the needs of nephrologists and clinic staff and administrators to deliver products that provide true value,a said Mark Costanzo, President, Renal Therapies Group of Fresenius Medical Care North America. aThe 2008T was designed to help physicians and clinic operators provide superior patient care as they adjust to new compliance guidelines and administrative pressures in the new bundled environment. The 2008T combines our next-generation, market-proven dialysis machine with an integrated, chair side IT terminal that we are confident will evolve how renal care decision making is performed in the clinic.a

The 2008T with CDX platform is designed to accommodate a wide range of MIS systems. Several major dialysis software vendors in the United States have already certified software for use with the 2008T. This versatile, innovative hemodialysis platform is designed to support many therapy-based and intradialytic applications in development at Fresenius Medical Care.

The 2008T is cleared for use by the U.S. Food and Drug Administration and Health Canada and is now available for purchase. Initial product demand has been significant, with pre-launch sales and pending orders. Fresenius Medical Care manufactures and distributes all hemodialysis delivery systems, including the 2008T, from its manufacturing facility in Walnut Creek, California.

aThis is a truly exciting development for those of us on the front lines of dialysis care,a said Ravi Kalathil, Chief Information Officer, Fresenius Medical Care North America. aThis is the first dialysis system that offers chair side access to complete patient information to guide therapy decisions and streamline data entry.a

About Fresenius Medical Care

Fresenius Medical Care (NYSE: FMS) is the worlda™s leading company devoted to patient-oriented renal therapy. Through nearly 2,600 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 199,000 patients worldwide. We are also the worlda™s leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 1.9 million individuals worldwide and the only treatments are a kidney transplant or dialysis.

For more information about the companya™s more than 1,800 U.S. dialysis facilities, visit [ www.ultracare-dialysis.com ] (in English and Spanish). For more information about Fresenius Medical Care, visit [ www.fmc-ag.com ] or [ www.fmcna.com ].

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaAa™s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Photos/MultimediaGallery Available:[ http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6516950&lang=en ]